Quilici S, Chancellor J, Maclaine G, McGuire A, Andersson D, Chiasson J-L
Innovus Research (UK) Ltd, High Wycombe, UK.
Int J Clin Pract. 2005 Oct;59(10):1143-52. doi: 10.1111/j.1368-5031.2005.00629.x.
We assessed the cost-effectiveness of acarbose in the management of patients with impaired glucose tolerance (IGT) in Sweden, based on progression to type 2 diabetes (T2D) and cardiovascular (CV) events reported in the STOP-NIDDM trial population, including high-risk subgroups. The cost per patient free from T2D was SEK28,000 or SEK1260 per diabetes free month prior to progression to T2D. The cost per patient free from CV events was SEK101,000 or SEK5000 per CV event free month. For the high CV risk subgroups, acarbose treatment dominated placebo (i.e. acarbose was more effective, less costly). Acarbose significantly reduces the incidence of diabetes and CV events in IGT patients. We predict this may translate into healthcare cost savings that partially or, in patients at high CV risk, fully offset the cost of acarbose. We conclude that acarbose is likely to be cost-effective in the management of impaired glucose tolerance.
我们基于在STOP-NIDDM试验人群（包括高危亚组）中报告的2型糖尿病（T2D）进展和心血管（CV）事件，评估了阿卡波糖在瑞典糖耐量受损（IGT）患者管理中的成本效益。在进展为T2D之前，每位未患T2D患者的成本为28,000瑞典克朗，或在未患糖尿病的月份中每月1260瑞典克朗。每位未发生CV事件患者的成本为101,000瑞典克朗，或在未发生CV事件的月份中每月5000瑞典克朗。对于高CV风险亚组，阿卡波糖治疗优于安慰剂（即阿卡波糖更有效且成本更低）。阿卡波糖可显著降低IGT患者的糖尿病和CV事件发生率。我们预计这可能转化为医疗成本节约，在部分患者或CV高风险患者中，可部分或完全抵消阿卡波糖的成本。我们得出结论，阿卡波糖在糖耐量受损的管理中可能具有成本效益。
